about
Rapid aneurysm growth and rupture in systemic lupus erythematosus3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long-term glucocorticoid users compared with controlsTreatment of ANCA-associated systemic vasculitis.Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritisInternational consensus for a definition of disease flare in lupus.Pseudo-pseudo Meigs' syndrome in a patient with systemic lupus erythematosus.Treatment of systemic lupus erythematosus - 2013 update.Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problem.Enterococcal arthritis with avascular necrosis in a lupus patient.Pulmonary metastasis in a patient with simultaneous bladder cancer and relapsing granulomatosis with polyangiitis.SLE: mechanisms of vascular injury.When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection.Gelatinous transformation of the bone marrow in systemic lupus erythematosus.Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission.Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program.Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.Clinical Reasoning: A 50-year-old woman with SLE and a tumefactive lesion.Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment.Aplastic anemia in systemic lupus erythematosus: a distinct presentation of acquired aplastic anemia?Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature reviewComplement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of diseaseSerum albumin at 1 year predicts long-term renal outcome in lupus nephritisFactors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective studyThe Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York CountyAssessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complementPostmenopausal hormone therapy and systemic lupus erythematosusNew York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritisIncreased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosusThe role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et alMisoprostol and Prednisone Treatment of Lupus NephritisThe effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trialAcute gastrointestinal distress syndrome in patients with systemic lupus erythematosusProliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanerceptThe Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and RepositoryAccelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopyAuthor Correction: Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathwaysTubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways
P50
Q35025422-7AB9471D-CA55-44F0-A759-5EC15BAB2C41Q36366288-7AACAE1F-5AF0-4F8E-8A58-2DCAE7A6C65DQ36661162-2D6CCD50-5C01-4A65-8691-DF1A50303798Q37294514-0E3DA940-2BA1-463B-8C32-17ACD46CE9BCQ37819549-B88CD2BD-1EC9-48D0-928E-C3D06FA56D41Q38043948-84A66889-045C-4B1D-A303-F3E7F4AF22FEQ38154946-9A05C9CC-6BF9-4D7F-A93D-9C437531E08CQ38806359-FCC0AFDF-DA15-412D-9ABA-92C54941C863Q40499757-E6E376C6-13AC-421C-B883-DF2EB53D384CQ41008790-9459EC6F-05E6-4E31-8670-A093228E18B7Q41233706-A55B76E9-8E87-47DF-9D99-777EF3F3AAEDQ41751834-7EF66056-E14D-4F49-B9A9-7C63BC756612Q42280855-EE416AD1-7D7A-4D8C-82B3-E68F42A575CBQ43275140-1C3144FF-2907-4B4A-97FB-C47EE8A32F91Q45914671-8D34351E-3BDD-4D27-8D52-5EFFF60057AFQ46224155-5CC581E2-5B07-4D43-B0C6-540B4A99848BQ47625192-953EE8EB-BA45-47CF-8A71-BE926F3BB3E0Q47680027-AD7D9A5E-1970-4584-BA6D-5A5ACDA0CDA3Q50035062-F7EE858F-AE70-4EBB-B382-AB5ACD232782Q50067383-FD355F53-ECC0-4660-B1A7-B41B9C6737C8Q53782926-60C8ADBF-3A6B-4B8E-ABCF-DD7A51A808B1Q57022521-5A10D433-A175-4414-9D80-2AC2B020ACC6Q57731137-C9145716-429E-450B-9C41-A389AAB8AF15Q58764611-464E43BA-01EC-4F76-A330-0BEBFBA3DED8Q64043122-DDAF6FB6-FB92-43EC-B306-6583A6B81810Q64136895-2C7C4263-5911-4C85-9139-73CA92F07C93Q67569108-343A2F2A-2401-4B0D-8493-C782DC85908EQ71555954-84EB1C95-3474-40EC-91F9-0C84FBA6AD41Q72345760-96F72E6B-CFCE-48DF-B099-A6522D086410Q73802358-E8FB4422-5572-4148-AB85-5515EE23D180Q74460411-EE020EF5-2554-4B7F-883B-45C4D6D34974Q77660590-B1578708-ACE5-44F2-95AC-2312A79E6483Q79318121-D64EE101-201A-4646-8824-389CFBD035AAQ80082599-32605EAA-9CBD-40CD-B966-E6192F9422BFQ81597324-8962340A-5E1F-4271-9D6D-97ABA5469F2FQ88399624-0B0B4485-7557-4ECE-9DCE-3F1D6E4D73BDQ90012316-14BB4110-6D79-449B-B612-D805AF1F18B7Q90478849-1B3BC27A-82E4-46FA-A7BB-99C9E3B6E51EQ90663992-46B3F9C3-2B0A-40C7-AC32-07B04690CA5FQ92173455-6147AA20-A295-4CFC-B111-72D47DEAAF83
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
H M Belmont
@ast
H M Belmont
@en
H M Belmont
@es
H M Belmont
@nl
type
label
H M Belmont
@ast
H M Belmont
@en
H M Belmont
@es
H M Belmont
@nl
prefLabel
H M Belmont
@ast
H M Belmont
@en
H M Belmont
@es
H M Belmont
@nl
P31
P496
0000-0003-3389-2976